跳转到内容

NITD008

维基百科,自由的百科全书
NITD008
臨床資料
商品名英语Drug nomenclatureNITD008
识别信息
  • (2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
CAS号1044589-82-3  checkY
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C13H14N4O4
摩尔质量290.28 g·mol−1
3D模型(JSmol英语JSmol
  • C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
  • InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1
  • Key:NKRAIOQPSBRMOV-NRMKKVEVSA-N

NITD008是一种抗病毒药物,属于腺苷类似物(一种核苷类似物英语nucleoside analog)。它作为治疗黄病毒英语flavivirus感染的潜在药物被开发,并显示出对很多相关病毒的广谱活性,如骨痛热症病毒西尼羅河病毒黄热病病毒波瓦桑病毒英语Powassan virus丙肝病毒克亚萨努尔森林病病毒英语克亚萨努尔森林病病毒鄂木斯克出血热病毒英语Omsk hemorrhagic fever virus茲卡病毒[1][2][3]然而,虽然NITD008在临床前的动物试验中显示出较大毒性,不适合人体试验,但是它仍被用于新型病毒性疾病治疗的研究中。[4]

参考文献

[编辑]
  1. ^ Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, et al. An adenosine nucleoside inhibitor of dengue virus. Proceedings of the National Academy of Sciences of the United States of America. December 2009, 106 (48): 20435–9. Bibcode:2009PNAS..10620435Y. PMC 2787148可免费查阅. PMID 19918064. doi:10.1073/pnas.0907010106可免费查阅. 
  2. ^ Lo MK, Shi PY, Chen YL, Flint M, Spiropoulou CF. In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses. Antiviral Research. June 2016, 130: 46–9. PMC 5096641可免费查阅. PMID 27016316. doi:10.1016/j.antiviral.2016.03.013. 
  3. ^ Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, et al. Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus. Open Forum Infectious Diseases. October 2016, 3 (4): ofw175. PMC 5063548可免费查阅. PMID 27747251. doi:10.1093/ofid/ofw175可免费查阅. 
  4. ^ Nelson J, Roe K, Orillo B, Shi PY, Verma S. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Research. October 2015, 122: 39–45. PMC 4853296可免费查阅. PMID 26225754. doi:10.1016/j.antiviral.2015.07.008.